AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters

Controversy over AstraZeneca's Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it's not all bad news for the British pharmaceutical company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.